Australia Hemophilia B Drugs Market Analysis

Australia Hemophilia B Drugs Market Analysis Summary

Australia Hemophilia B Drugs Market is valued at around $0.14 Bn in 2022 and is projected to reach $0.23 Bn by 2030, exhibiting a CAGR of 6.3% during the forecast period 2023-2030.

Clotting factor IX, often known as the Christmas factor, deficiency or dysfunction is the primary cause of the inherited bleeding condition haemophilia B. The World Federation of Hemophilia (WFH) has estimated that Hemophilia B affects roughly 1 in 25,000 male births worldwide. Hemophilia B's pathophysiology includes problems in the intrinsic pathway of the clotting cascade. Hemophilia B patients generally have prolonged Activated Partial Thromboplastin Time (aPTT), which is indicative of clotting factor IX deficiency. The factor IX assay test assesses the presence and activity of factor IX, a clotting agent, in the blood. When compared to healthy people, those with haemophilia B will have much lower levels of factor IX. The primary cause of the inherited bleeding disorder haemophilia B is a deficit or malfunction of clotting factor IX, also known as the Christmas factor. According to estimates from the World Federation of Hemophilia (WFH), Hemophilia B affects about 1 in 25,000 male births globally. The intrinsic pathway of the clotting cascade is affected in the pathophysiology of haemophilia B. A prolonged Activated Partial Thromboplastin Time (aPTT), a sign of clotting factor IX deficiency in haemophilia B patients, is typical. The factor IX assay test determines whether factor IX, a clotting agent, is present and active in the blood. When compared to healthy people, those with haemophilia B will have much lower levels of factor IX.A thorough physical examination is performed to look for any bleeding indicators, such as joint swelling, bruising, or proof of prior bleeding episodes. Gene therapy, Recombinant Factor IX Products such as BeneFIX (Nonacog alfa), Plasma-Derived Factor IX Concentrates like AlphaNine SD (Coagulation factor IX human):, Extended Half-Life Factor IX Products like Alprolix (Eloctate). BeneFIX (Nonacog alfa) and AlphaNine SD (Coagulation factor IX human) have the highest market share which is further expected to grow. However, the market for Hemophilia B Drugs is smaller compared to Hemophilia A due to the lower prevalence of Hemophilia B.

Notable players in the market include BioMarin Pharmaceutical Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, CSL Behring LLC, Takeda Pharmaceutical Company Limited (formerly Shire), Sanofi S.A., Grifols S.A., and Octapharma AG, among others.

Market Dynamics

Market Drivers

The Hemophilia B market is influenced by several key drivers that shape its growth and development. These drivers include:

Increasing Awareness: The need for better diagnosis, treatment choices, and patient care is being driven by a rising awareness of Hemophilia B among medical professionals, patients, and the general public. For people with haemophilia B, more knowledge results in earlier discovery, proper management, and improved outcomes.

Advancements in Treatment: Gene therapy and the creation of extended half-life (EHL) factor IX concentrates are only two examples of the significant improvements made in Hemophilia B treatment options. These cutting-edge treatments boost patient convenience, decrease treatment frequency, and improve efficacy, spurring market expansion.

Rising Patient Population: Hemophilia B incidence and prevalence have a big impact on market dynamics. Even though Hemophilia B is a less common condition than Hemophilia A, rising awareness, better diagnostic tools, and greater access to healthcare have helped identify more instances, which has helped the market increase.

Government Support and Funding: The market is expanding as a result of government measures that support patients with haemophilia B through financial programmes, healthcare regulations, and advocacy efforts. Public financing can promote research and development, increase patient access to care, and improve overall Hemophilia B patient care. For Instance, In the United States, the Centers for Disease Control and Prevention (CDC) supports a network of Hemophilia Treatment Centers (HTCs) that provide comprehensive care for individuals with Hemophilia B.

Technological Advancements: Genetic testing and next-generation sequencing are two examples of cutting-edge technologies that have increased the precision and usability of diagnostic tools for haemophilia B. These developments have a favourable effect on the market since they support early diagnosis, genetic counselling, and individualised treatment plans.

Market Restraints

High Cost of Treatment, Inhibitor Development and neutralizing antibodies development by some patients against factor replacement therapies, need for regular infusions by patients and limited understanding of the disease are market growth restraints.

Development in Hemophilia B Drugs Market Analysis:

In May 2023- The U.S. Food and Drug Administration (FDA) has granted fast track designation to SerpinPC, Centessa Pharmaceuticals’ investigational treatment for people with hemophilia B. Drug is novel inhibitor of activated protein C administered subcutaneously.